Stereotaxis Technology, Clinical Value and Innovations to be Highlighted at Society for Cardiac Robotic Navigation Meeting

Rhea-AI Summary

Stereotaxis (NYSE: STXS) has announced its participation in the Fifth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) on November 12-13, 2021. This hybrid event will showcase discussions on innovations in cardiac robotics, including presentations on energy sources, automated navigation for atrial fibrillation, and TeleRobotic collaborations. The SCRN aims to foster clinical awareness and technology advancement in cardiology. Stereotaxis continues to lead in robotic technology for arrhythmias, emphasizing its commitment to improving patient care.

Positive

• Participation in the prestigious SCRN meeting enhances brand visibility and credibility.
• Showcasing advanced robotic technologies may attract interest from potential clients and investors.
• The focus on innovative solutions positions Stereotaxis as a leader in the evolving field of cardiac care.

Negative

• None.

ST. LOUIS, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announces it will attend the Fifth Annual International Meeting of the Society for Cardiac Robotic Navigation (SCRN) on November 12-13.

SCRN is an independent, non-profit, physician-led organization with global membership and local chapters in North America, Europe and Asia. SCRN was formed with the mission to advance clinical awareness, scientific research and technology innovation for robotic technologies in cardiology. The SCRN meeting hosts cardiologists, fellows, innovators, industry leaders and scientists to debate, discuss, challenge, share, educate and learn with peers.

The hybrid in-person and virtual event includes several presentations on Stereotaxis’ technology, clinical value and innovations. The full agenda is available on the SCRN website. Certain presentations of note include those on new energy sources used with robotics (Dr. Steven Mickelsen), adoption of robotics in healthcare systems (Dr. Srijoy Mahapatra and Dr. Dhanunjaya “DJ” Lakkireddy), automated navigation for atrial fibrillation (Dr. Usman Siddiqui), TeleRobotic and remote collaboration (Prof. Sabine Ernst), robotic integration with Acutus’ AcQMap system (Dr. Tamas Szili-Torok and Dr. Margot Vloka), and the use of robotics in treating ventricular tachycardias (Dr. J. David Burkhardt and Dr. Amin Al-Ahmad). The meeting is being hosted by SCRN President, Dr. J. Peter Weiss, along with Dr. Pedram Kazemian and Dr. Gurjit Singh.

“Stereotaxis continues to be at the forefront of innovation in cardiac robotics, and I appreciate their continued investment in technologies to advance our field,” said Dr. Weiss. “We are excited by the growth of SCRN and look forward to an exceptional faculty at this year’s meeting.”

“We are honored to join such a prestigious group of physicians and thought leaders at the Society for Cardiac Robotic Navigation’s annual meeting,” said David Fischel, chairman and CEO of Stereotaxis. “Our mission is driven by the ambitions of those who are willing to challenge the boundaries of technology and patient care in healthcare.”

About Stereotaxis
Stereotaxis (NYSE: STXS) is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis’ Robotic Magnetic Navigation technology is used in the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com or follow us on Facebook, Twitter, LinkedIn, Instagram, and YouTube.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
investors@stereotaxis.com

FAQ

What is the significance of Stereotaxis attending the SCRN meeting on November 12-13?

Stereotaxis's attendance at the SCRN meeting is significant as it showcases its innovative robotic technologies and strengthens its position within the cardiology community.

What topics will be discussed at the SCRN meeting that relate to Stereotaxis?

Topics include new energy sources for robotic systems, automated navigation for atrial fibrillation, and the integration of robotics with other medical technologies.

How does Stereotaxis contribute to advances in cardiac robotics?

Stereotaxis contributes by developing robotic technologies that enhance treatment capabilities for cardiac arrhythmias, aiming to improve patient outcomes.

What advancements in robotic technology can be expected from Stereotaxis?

Expect advancements in energy sources used in robotics, automated navigation, and collaborations with systems like Acutus' AcQMap for enhanced procedural integration.